Blocking the Signal: Novel Compounds Show promise in Disrupting Cancer-driving RAS Pathway
For decades,the RAS gene has stood as a formidable challenge in cancer research. Mutated in roughly 20% of all cancers, its relentless signaling drives uncontrolled cell growth and proliferation. Now, a groundbreaking collaboration between scientists at the Francis Crick Institute and Vividion Therapeutics has yielded a potential breakthrough: a new class of chemical compounds capable of selectively disrupting the interaction between RAS and a critical downstream pathway, offering a targeted approach wiht the potential to treat a wide spectrum of cancers while minimizing debilitating side effects. This promising treatment is now entering its first phase of human clinical trials.
The RAS Challenge: Why blocking This Gene Has Been so Challenging
The RAS gene functions as a crucial on/off switch in cellular interaction, initiating a cascade of events that regulate cell growth and division. When mutated, this switch gets stuck in the ”on” position, relentlessly signaling cells to divide. Directly shutting down RAS itself, or the enzymes it activates, has proven elusive. These same pathways are fundamental to normal cellular function – impacting everything from immune response to basic metabolic processes.
A prime example is PI3K, an enzyme closely linked to RAS signaling. PI3K also plays a vital role in insulin regulation and blood sugar control. Complete PI3K inhibition leads to significant side effects, notably hyperglycemia, rendering it an unsuitable target for broad-spectrum cancer therapy. The key, therefore, isn’t to shut down the pathway entirely, but to specifically interrupt the aberrant signaling caused by mutated RAS.
A Precision approach: Targeting the RAS-PI3K Interaction
Published October 9th in Science, the research details a sophisticated strategy combining high-throughput chemical screening with rigorous biological validation. Vividion Therapeutics researchers identified a series of small molecules designed to bind to the surface of PI3K, specifically at the site where RAS normally attaches.
Crucially, these compounds don’t block all of PI3K’s functions. Using a novel assay developed by the Crick Institute team, researchers confirmed that the compounds effectively prevented the RAS-PI3K interaction while allowing PI3K to continue performing its essential roles, including insulin signaling. This precision is the cornerstone of the potential for reduced side effects.
Promising Results in Preclinical Models
Initial testing in mice bearing RAS-mutated lung tumors demonstrated remarkable results. The new compound effectively halted tumor growth without triggering elevated blood sugar levels. Further bolstering its potential, the treatment exhibited synergistic effects when combined with existing drugs targeting other components of the same signaling pathway, leading to even more robust and sustained tumor suppression.
The research extended beyond RAS-driven cancers. Testing in mice with tumors harboring mutations in HER2 - a gene frequently overexpressed in breast cancer and also known to interact with PI3K – revealed similar tumor-inhibiting effects, even autonomous of RAS. This suggests the compound’s mechanism of action may extend to a broader range of cancers than initially anticipated.
Clinical Trials Underway: A New Hope for Patients
The drug has now progressed to Phase 1 clinical trials, designed to assess safety and identify potential side effects in humans with both RAS and HER2 mutations. The trial will also investigate the efficacy of combining the new compound with existing RAS-targeted therapies.
“Given the RAS gene is mutated across a wide range of cancers, we’ve been exploring how to stop it interacting with cell growth pathways for many years, but side effects have held back the development of treatments,” explains Julian Downward, Principal Group Leader of the Oncogene Biology laboratory at the Crick. “our collaborative effort has overcome this challenge by targeting the PI3K and RAS interaction specifically,leaving PI3K free to bind with its other targets. It’s exciting to see these clinical trials starting, highlighting the power of understanding chemistry and fundamental biology to get to something with potential to help people with cancer.”
Matt Patricelli, Ph.D., Chief Scientific Officer of Vividion, echoes this sentiment: “This finding is a great example of how new discovery approaches can open up entirely novel ways to tackle cancer. By designing molecules that stop RAS and PI3K from connecting,while still allowing healthy cell processes to continue,we’ve found a way to selectively block a key cancer growth signal. It’s incredibly rewarding to see this science now progressing in the clinic, where it has the potential to make a real difference for patients.”
Looking Ahead: A Paradigm Shift in Cancer Treatment?
this research represents a significant step forward in the fight against cancer.By focusing on disrupting a specific protein-protein interaction – RAS and PI3K - rather than attempting to broadly inhibit entire pathways, scientists have created a potential treatment with a more favorable safety profile and broader applicability. The ongoing clinical trials will be critical in determining the efficacy and
Related reading